In Enterobacterales bacteremia, antipseudomonal β-lactam de-escalation was noninferior to continuation for clinical cure at 3 to 5 d
- PMID: 38710092
- DOI: 10.7326/J24-0030
In Enterobacterales bacteremia, antipseudomonal β-lactam de-escalation was noninferior to continuation for clinical cure at 3 to 5 d
Abstract
López-Cortés LE, Delgado-Valverde M, Moreno-Mellado E, et al; SIMPLIFY study group. Efficacy and safety of a structured de-escalation from antipseudomonal β-lactams in bloodstream infections due to Enterobacterales (SIMPLIFY): an open-label, multicentre, randomised trial. Lancet Infect Dis. 2024;24:375-385. 38215770.
Conflict of interest statement
Comment on
-
Efficacy and safety of a structured de-escalation from antipseudomonal β-lactams in bloodstream infections due to Enterobacterales (SIMPLIFY): an open-label, multicentre, randomised trial.Lancet Infect Dis. 2024 Apr;24(4):375-385. doi: 10.1016/S1473-3099(23)00686-2. Epub 2024 Jan 9. Lancet Infect Dis. 2024. PMID: 38215770 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical